Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 17;8(7):ofab254. doi: 10.1093/ofid/ofab254

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Frequency of 28-day study outcomes among propensity-matched patients receiving and not receiving bamlanivimab monoclonal antibody treatment. (a) depicts the frequency of 28-day hospitalization or mortality 408 (primary outcome) and hospitalization or emergency department (ED) visit without hospitalization (secondary outcome) among the matched patients receiving bamlanivimab monoclonal antibody treatment (orange bars) versus those not receiving bamlanivimab monoclonal antibody treatment (blue bars). (b) depicts the frequency of the individual elements of the composite primary and secondary outcomes. P values are from the matched cohort logistic regression models.